KZA kazia therapeutics limited

Very impressive 2020 AGM Chairman's address and CEO presentation...

  1. 1,206 Posts.
    lightbulb Created with Sketch. 941
    Very impressive 2020 AGM Chairman's address and CEO presentation last Friday.

    Kazia's anticipated Key Milestones and Newsflow schedule over the next 7.5 months is incredible for a company of our size.

    In particular looking forward to the interim data from both :-
    Initial interim data from phase II BCBM trial at Dana-Farber - Q4 CY2020
    Initial interim data from phase II brain mets study by Alliance Group - H1 CY2021

    IMO any favorable paxalisib published data from either study, will finally see Genentech extremely interested in PAXALISIB and participate in discussions at the negotiation table.

    Regards.

    https://hotcopper.com.au/data/attachments/2631/2631269-23027925b67b0e3510fc7e8416209347.jpg


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.